Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Population
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA-crafted labeling for Amgen’s Sensipar anticipates off-label use of the secondary hyperparathyroidism therapy in pre-dialysis patients, review documents for the NDA show.